Hospitals can't see inside AI tools, AHA tells FDA

The American Hospital Association urges the FDA to hold AI developers accountable for ongoing monitoring and performance of generative AI medical devices, citing hospitals' lack of visibility and resources to independently evaluate these tools. The AHA recommends a risk-based regulatory framework with clear post-market evaluation standards and enhanced labeling to protect patients without stifling innovation.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure, and 3 sources have reported it between 19 Oct 2026 and 21 Oct 2026.